Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
A selection of key takeaways includes:
The meaningful survival benefit demonstrated by pelareorep-based treatment combinations in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC) patients across randomized and single-arm clinical studies necessitates evaluating pelareorep in a registration-enabling study in 1L mPDAC.
Immunotherapies have not yet been approved to treat mPDAC patients, illustrating an unmet need, which provides an opportunity for an immunologically active agent like pelareorep to deliver an impactful clinical benefit in this challenging indication.
The combination of pelareorep and chemotherapy would be an appealing treatment option for 1L mPDAC patients, even with the presence of RAS inhibitors in the treatment paradigm.
Translational data from multiple mPDAC and colorectal cancer clinical trials validate pelareorep's mechanism of action, showing that it replicates in tumors, stimulates chemokine expression, and induces the expansion of tumor-infiltrating lymphocytes (TILs), which correlates with a reduction in tumor size.
"I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event," said Jared Kelly, Chief Executive Officer of Oncolytics. "Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers."
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @ oncolytics.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our commitment to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
Company Contact
Jon Patton
Director of IR & Communication
[email protected]
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]
Media Contact for Oncolytics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
Altisource Q2 Revenue Up 11 Percent
Key Points - Revenue (GAAP) rose 11% to $43.3 million in Q2 2025, reflecting year-over-year improvement in Adjusted EBITDA across both major business segments. - Net income turned positive at $16.6 million, driven by an $18.5 million one-time tax reserve reversal for India in Q2 2025. - But underlying operating cash flow (non-GAAP) remained negative. These 10 stocks could mint the next wave of millionaires › Altisource Portfolio Solutions (NASDAQ:ASPS), a provider of services and technology for the mortgage and real estate industries, published its Q2 2025 earnings on July 24, 2025. The most notable news was a sharp swing to positive net income (GAAP), largely due to a substantial tax benefit from reversing reserves tied to prior uncertainties with Indian tax positions. Revenue climbed 11% to $43.3 million, up from $39.1 million in the same quarter last year, with adjusted EBITDA (non-GAAP) rising 23% to $5.4 million. With no available analyst consensus, it is not possible to gauge this quarter's results against Street expectations. Overall, the second quarter showed stronger service revenue and profitability compared to the same period in 2024, but the headline numbers were heavily influenced by non-operational gains and persistent cash outflows. Metric Q2 2025 Q2 2024 Y/Y Change Diluted EPS (GAAP) $1.48 ($2.33) $1.86 Adjusted Diluted EPS (Non-GAAP) $0.19 ($1.67) — Revenue (GAAP) $43.3 million $39.1 million 11% Adjusted EBITDA (Non-GAAP) $5.4 million $4.4 million 23% Net Income (GAAP) $16.6 million ($8.3 million) $24.9 million Business Overview and Strategic Focus Altisource is a specialized services and technology company concentrated in the mortgage, real estate, and loan origination markets. It offers a portfolio of technology platforms and business process services supporting mortgage servicing, property management, and mortgage origination. Key product lines include technology solutions such as Equator, a loan servicing platform, and RentRange, which provides data analytics for real estate investment. Its growth strategy depends on deep relationships with major clients, technology-enabled solutions, and effective management of debt and overall financial leverage. One customer, Onity, accounts for a substantial portion of revenue, leading to client concentration risk. The company also emphasizes innovation in software-as-a-service (SaaS) and automation, while actively managing debt and seeking opportunities in evolving regulatory and market conditions. Quarter Highlights: Revenue Growth, One-Off Gains, and Debt Moves During Q2 2025, Altisource saw service revenue rise 11%, supported by improvements in Adjusted EBITDA in both the Servicer and Real Estate, and Origination segments. Service revenue increased by $3.9 million year over year, Segment-level margins increased slightly. However, gross margin on service revenue dipped from 34% in Q2 2024 to 32% in Q2 2025 (GAAP). This decline occurred despite top-line growth. The most significant profit driver was the $18.5 million reversal of reserves related to uncertain Indian tax positions, including $9.6 million for taxes and $9.0 million for accrued interest. This non-operational item transformed the company's net income for the period; without it, adjusted net income would have been much lower at $2.2 million (non-GAAP). Excluding this effect, adjusted diluted earnings per share (non-GAAP) moved to $0.19 from a loss a year earlier, demonstrating improvement, but on a much smaller scale than the GAAP figures. Debt reduction and restructuring were also major features. After a term loan exchange in Q1 2025, long-term debt consisted of a $160.0 million senior secured term loan and a $12.5 million super senior term loan, compared to $232.8 million at the end of 2024, aided by a $12.5 million Super Senior facility and $45.4 million in equity issued in exchange for debt. Net debt (non-GAAP) at quarter end was $142.2 million. This reduction is expected to lower annual GAAP interest expense to approximately $9.5 million, creating future savings in cash flow and improving the balance sheet. The company also implemented a 1-for-8 reverse stock split on May 28, reducing shares outstanding and altering share price dynamics. Despite the positive headline results, operating cash flow (GAAP) remained negative at ($0.3) million for the quarter and ($5.3) million for the first six months of 2025. Negative cash flow from operations (GAAP) signals continued pressure on the ability to fund future investments internally, even as the company works to stabilize its financial base. Corporate and other segment losses offset improvements in the main business lines, underscoring ongoing challenges with cost discipline outside core operating units. No dividend was declared or paid during the quarter. ASPS does not currently pay a dividend. Industry and Market Context Market conditions during the quarter shaped Altisource's growth in important ways. The broader mortgage industry saw a modest pickup: foreclosure initiations were up 22% for the five months ended May 31, 2025 compared to the same period in 2024, but volumes remain well below pre-pandemic levels, with foreclosure initiations still 22% lower than in 2019 and foreclosure sales 51% below that benchmark for the same period. Mortgage origination volumes rose 14% for the six months ended June 30, 2025 compared to the same period in 2024, driven mainly by a 58 % jump in refinancing activity, while purchase activity fell slightly. However, management noted that the current environment remains 'close to historically low' in terms of industry delinquencies, continuing to constrain organic growth for foreclosure- and default-related services, as referenced in recent disclosures. The company reported some wins in new business during the period, estimating annualized stabilized service revenue from sales wins of $1.1 million in its Servicer and Real Estate business and $3.3 million in Origination. Technology remains a central theme, but the company reported no quantitative progress on platforms like Equator or in SaaS adoption metrics. Management continues to describe technology-enabled solutions as an area of focus, yet offered no new data to measure this area's contribution during the period. Regulatory factors impacted results through the tax reversal in India—removing significant uncertainty and legal overhang. Though management underscored that regulation remains an ever-present aspect of operating in the mortgage and real estate services sector. Outlook and What to Watch Management offered no explicit financial guidance for the next quarter or the full year. Executives highlighted their expectation that higher industry defaults and foreclosure volumes would boost results in Altisource's most profitable business lines. They noted a weighted average sales pipeline between $36 million and $44 million in potential annualized service revenue, with the majority of future opportunities likely to be realized in 2026 and beyond. The company remains focused on growing business lines with favorable industry trends, managing costs, and building financial flexibility following the recent debt restructuring. Investors may want to monitor whether operating cash flow can turn positive, how well sales pipeline wins convert to recurring revenues, and any changes in client concentration or major contract renewals. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,037%* — a market-crushing outperformance compared to 182% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 21, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Globe and Mail
an hour ago
- Globe and Mail
Frontera Energy Provides Notice of Second Quarter 2025 Financial Results Conference Call
CALGARY, AB, July 24, 2025 /CNW/ - Frontera Energy Corporation (TSX: FEC) (" Frontera" or the " Company") announces that the Company will release its financial and operational results for the second quarter ended June 30, 2025, after markets close on Wednesday, August 13th, 2025.
Cision Canada
an hour ago
- Cision Canada
Frontera Energy Provides Notice of Second Quarter 2025 Financial Results Conference Call
CALGARY, AB, July 24, 2025 /CNW/ - Frontera Energy Corporation (TSX: FEC) (" Frontera" or the " Company") announces that the Company will release its financial and operational results for the second quarter ended June 30, 2025, after markets close on Wednesday, August 13th, 2025. A conference call for investors and analysts will be held on Thursday, August 14th, 2025, at 11:00 p.m. Eastern Time. Participants will include Gabriel de Alba, Chairman of the Board of Directors, Orlando Cabrales, Chief Executive Officer, René Burgos, Chief Financial Officer, and other members of the senior management team. Analysts and investors are invited to participate using the following dial-in numbers: A replay of the conference call will be available until 11:59 p.m. Eastern Time on August 21st, 2025. About Frontera: Frontera Energy Corporation is a Canadian public company involved in the exploration, development, production, transportation, storage and sale of oil and natural gas in South America, including related investments in both upstream and midstream facilities. The Company has a diversified portfolio of assets with interests in 22 exploration and production blocks in Colombia, Ecuador and Guyana, and pipeline and port facilities in Colombia. Frontera is committed to conducting business safely and in a socially, environmentally and ethically responsible manner.
